Loading…
Loading…
MVRBF (Medivir AB (publ)) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MVRBF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MVRBF and 80,000+ other tickers.
See exactly how MVRBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MVRBF and 80,000+ other tickers.
Medivir AB (publ), established in 1987 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to the discovery, development, and commercialization of medicines, with a primary emphasis on oncology. The company's operations span both Sweden and international markets. Currently, Medivir markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its pipeline of developmental compounds includes Remetinostat, an investigational therapy for MF cutaneous T-cell lymphoma and basal cell carcinoma. Additionally, the company is advancing MIV-818 for liver cancer…
Medivir AB (publ) (MVRBF) Q4 2025 Earnings Call Transcript
Medivir AB (publ) (OTC:MVRBF) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants Jens Lindberg - Chief Executive Officer Pia Baumann - Chief Medical Officer Fredrik Öberg - Chief Scientific Officer Magnus Christensen - Chief Financial Officer Conference Call Participants Richard Ramanius - Redeye AB, Research Division Presentation Operator Welcome to Medivir Q3 Report 2025. [Operator Instructions] Now I will hand the conference over to CEO, Jens Lindberg.
STOCKHOLM , Sept. 18, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the Pareto Securities Healthcare Conference tomorrow, September 19.
STOCKHOLM , Feb. 26, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm : MVIR) today announces that that the nomination committee before the annual general meeting in May 2024 changes as follows. Anders Hallberg is leaving the nomination committee and HealthInvest Partners has declined new representation in the nomination committee.
STOCKHOLM , Nov. 7, 2023 /PRNewswire/ -- The shareholders in Medivir AB (publ) reg. no. 556238-4361 (the "Company") are hereby convened to the extraordinary general meeting, which will be held on Friday 1 December 2023, at 10.00 CET at Helio GT30, Grev Turegatan 30, Stockholm, Sweden.